US FDA takes step to change peptide compounding policy
XLV•The FDA and Department of Health and Human Services submitted an interim policy on compounding certain peptides for White House review. The policy would reportedly allow pharmacies to make some popular peptides, including BPC-157, but the filing provided no details.
1. Policy sent for review
The FDA and Department of Health and Human Services submitted an “interim access policy for compounding using certain peptides” to the White House for review, according to a filing on the Office of Management and Budget website. The filing did not provide details.
2. Peptides under consideration
Advisers recommended in July that the FDA loosen restrictions on six of seven peptides under review, including BPC-157. The peptides have not been approved by the FDA as safe or effective. Hims & Hers Health had previously said it plans to offer peptides if regulations permit.
